Update on a dementia therapeutic moving toward a pivotal registrational study after promising psychosis-reduction results in earlier trials.
Key Takeaways
- FDA agreed psychosis associated with dementia with Lewy bodies could be approvable
- Company will use the Neuropsychiatric Inventory as a novel primary endpoint
- Phase 2 analysis reportedly showed the drug slowed hallucinations and delusions by 89%